CombiMatrix Corporation (CBMX)
CombiMatrix Corporation R&D Expense: 0.45M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CBMX R&D Expense Rankings
| Overall | 74th percentile | 453 of 1764 |
| Sector | 88th percentile | 48 of 413 in Healthcare |
| Industry | 66th percentile | 5 of 15 in Medical Laboratories & Research |
CBMX R&D Expense Range, Past 5 Years
| Minimum | 0.073M | Dec 2010 |
| Maximum | 1.924M | Sep 2007 |
| Average | 0.7862M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these CBMX related companies
CBMX News
$CBMX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3smq
about 11 days ago by MarketBrief
about 11 days ago by MarketBrief
CombiMatrix Corporation to Release First Quarter Financial Results on May 11, 2012
May 04, 6:00AM GlobeNewswire
May 04, 6:00AM GlobeNewswire
CombiMatrix Appoints Richard Ding and Joseph M. Limber to Board of Directors
Mar 01, 6:00AM GlobeNewswire
Mar 01, 6:00AM GlobeNewswire
CombiMatrix Corporation to Release Fourth Quarter and Twelve-Month Financial Results on February 29, 2012
Feb 22, 6:00AM GlobeNewswire
Feb 22, 6:00AM GlobeNewswire
Greggory Schneider reports 5.02% stake in CombiMatrix, may talk with management
Nov 14, 3:15PM FlyOnTheWall
Nov 14, 3:15PM FlyOnTheWall
CombiMatrix Corporation to Release Third Quarter and Nine-Month Financial Results on November 10, 2011
Nov 03, 6:00AM GlobeNewswire
Nov 03, 6:00AM GlobeNewswire
David H. Ledbetter, PH.D., FACMG Joins CombiMatrix Medical Advisory Board
Oct 04, 6:00AM GlobeNewswire
Oct 04, 6:00AM GlobeNewswire
CombiMatrix to Present at the 2011 Southern California Investor Conference
Aug 22, 6:00AM GlobeNewswire
Aug 22, 6:00AM GlobeNewswire
CombiMatrix Corporation to Release Second Quarter and Six-Month Financial Results on August 10, 2011
Aug 03, 6:00AM GlobeNewswire
Aug 03, 6:00AM GlobeNewswire
disclosure: I own $CBMX with an avg. price of 7.16 -- my target is a double.
about 993 days ago by ari5000
about 993 days ago by ari5000
here's your first free monster pick: $CBMX : please do ur own research. I'm not responsible for your monster wins, or possible losses.
about 993 days ago by ari5000
about 993 days ago by ari5000
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBMX | 0.92 | -0.04 | -4.17% | 9.844M |
| CBM | 7.08 | +0.00 | +0.00% | 209.71M |
| BRS | 43.38 | -0.33 | -0.76% | 1.548B |
| BRO | 25.69 | -0.17 | -0.66% | 3.683B |
| BRN | 3.25 | +0.00 | +0.00% | 26.91M |
| BRLI | 20.38 | +0.04 | +0.20% | 569.62M |
| BRKS | 9.69 | +0.01 | +0.10% | 641.96M |
| BRKR | 15.12 | +0.20 | +1.34% | 2.508B |
| BRK.B | 79.25 | -0.55 | -0.69% | 196.25B |
| CBI | 37.12 | -0.53 | -1.41% | 3.628B |
